SubsidieMeestersFirst ever preventive treatment for celiac disease and gluten sensitivity
E40 is a novel gluten-degrading enzyme designed to improve quality of life for Celiac and gluten-sensitive individuals by reducing gluten's inflammatory effects during digestion.
Projectdetails
Introduction
E40 is a novel gluten degrading enzyme aimed at enhancing the degradation of ingested gluten, particularly in gluten intolerant Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) sufferers.
Unique Features
Different from any other competing enzymes under development, E40 efficiently exerts its gluten degrading activity in both the stomach and the intestine of CeD and NCGS sufferers, supporting the benefits of a Gluten Free Diet (GFD). The final goal is to prevent symptomatology due to the pro-inflammatory reaction triggered by gluten.
Benefits for Sufferers
E40 will allow sufferers to manage inadvertent gluten exposure and will improve the sufferer's Quality of Life. In particular, it will enable them to normalize their work and social life, reducing anxiety and allowing them to enjoy many everyday activities, such as:
- Eating in a restaurant
- Travelling
- Visiting their friends in their homes
Production and Validation
E40 is produced by an engineered, patented acidic Streptomyces lividans TK24 strain, and directly purified in its mature, functional form. E40 activity has already been confirmed using the validated human simulated digestion INFOGEST assay of real food digestion. E40 gluten degradation leads to a gluten-free status (residual gluten <20ppm as per EC guidelines).
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 4.243.109 |
Tijdlijn
| Startdatum | 1-6-2023 |
| Einddatum | 31-5-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- NEMYSIS LIMITEDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)The project aims to develop a novel treatment for celiac disease using a combination of gliadin protein, probiotic particles, and mouth patch technology, targeting market entry by 2029. | EIC Accelerator | € 2.499.993 | 2022 | Details |
Development of a natural therapeutic treatment for late-stage lung cancer patientsCeltic Biotech aims to conduct Phase I Part 3 trials for CB24, a home-administered treatment for NSCLC, to secure regulatory approval and establish it as a safe, effective cancer therapy. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Novel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)
The project aims to develop a novel treatment for celiac disease using a combination of gliadin protein, probiotic particles, and mouth patch technology, targeting market entry by 2029.
Development of a natural therapeutic treatment for late-stage lung cancer patients
Celtic Biotech aims to conduct Phase I Part 3 trials for CB24, a home-administered treatment for NSCLC, to secure regulatory approval and establish it as a safe, effective cancer therapy.
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.
GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Tracking gluten immunoreactive peptides from the grain to the gut and beyondGLUTENOMICS aims to identify and analyze gluten immunoreactive peptides in human biosamples to improve grain-based food tolerability and prevent wheat-related disorders. | ERC Starting... | € 1.499.988 | 2022 | Details |
Voedingssupplement voor de preventie van coeliakieOnderzoek naar de haalbaarheid van een voedingssupplement ter preventie van coeliakie, gericht op technische en economische aspecten. | Mkb-innovati... | € 20.000 | 2021 | Details |
Bugs4Urate - Precision Nutrition Strategies for Investigating Probiotic, Diet, Glycan, and Microbiome Factors in Hyperuricemia and Gout PreventionThis project aims to develop a precision nutrition approach using a novel probiotic to lower urate levels and prevent gout by analyzing gut microbiome interactions and individual responses. | EIC Pathfinder | € 3.765.840 | 2024 | Details |
INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTHiNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment. | EIC Pathfinder | € 3.194.343 | 2025 | Details |
Enteric Bioelectronics for Sensing and Stimulating the CNSEnterBio aims to develop bioelectronic tools for non-invasive modulation of the enteric nervous system to improve treatment of neurological disorders by leveraging gut-brain interactions. | EIC Pathfinder | € 2.634.485 | 2024 | Details |
Tracking gluten immunoreactive peptides from the grain to the gut and beyond
GLUTENOMICS aims to identify and analyze gluten immunoreactive peptides in human biosamples to improve grain-based food tolerability and prevent wheat-related disorders.
Voedingssupplement voor de preventie van coeliakie
Onderzoek naar de haalbaarheid van een voedingssupplement ter preventie van coeliakie, gericht op technische en economische aspecten.
Bugs4Urate - Precision Nutrition Strategies for Investigating Probiotic, Diet, Glycan, and Microbiome Factors in Hyperuricemia and Gout Prevention
This project aims to develop a precision nutrition approach using a novel probiotic to lower urate levels and prevent gout by analyzing gut microbiome interactions and individual responses.
INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTH
iNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment.
Enteric Bioelectronics for Sensing and Stimulating the CNS
EnterBio aims to develop bioelectronic tools for non-invasive modulation of the enteric nervous system to improve treatment of neurological disorders by leveraging gut-brain interactions.